Thalidomide is frequently used in patients with newly diagnosed and relapsed multiple myeloma, but its role as maintenance therapy following autologous stem-cell transplantation has been an area of uncertainty. In this article we consider the efficacy of thalidomide maintenance therapy in multiple myeloma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Spencer, A. et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J. Clin. Oncol. 27, 1788–1793 (2009).
D'Amato, R. J., Loughman, M. S., Flynn, E. & Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl Acad. Sci.USA 91, 4082–4085 (1994).
Vacca, A. et al. Bone marrow angiogenesis and progression in multiple myeloma. Br. J. Haematol. 87, 503–508 (1994).
Singhal, S. et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341, 1565–1571 (1999).
Palumbo, A. et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367, 825–831 (2006).
Rajkumar, S. V., Blood, E., Vesole, D., Fonseca, R. & Greipp, P. R. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol. 24, 431–436 (2006).
Stewart, A. K. et al. Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin. Cancer Res. 10, 8170–8176 (2004).
Attal, M. et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108, 3289–3294 (2006).
Barlogie, B. et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N. Engl. J. Med. 354, 1021–1030 (2006).
Morgan, G. J. et al. Maintenance thalidomide may improve progression free but not overall survival; results from the myeloma IX maintenance randomisation [abstract]. Blood (ASH Annual Meeting Abstracts) 112, 656 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
P. Richardson is an Advisory Board member for Celgene and Millenium. K Anderson is a Consultant and receives research/grant support from Celgene and Millenium.
Rights and permissions
About this article
Cite this article
Laubach, J., Richardson, P. & Anderson, K. Thalidomide maintenance in multiple myeloma. Nat Rev Clin Oncol 6, 565–566 (2009). https://doi.org/10.1038/nrclinonc.2009.131
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2009.131